ArticleInternational journal of molecular sciences2021
Berberine Delays Onset of Collagen-Induced Arthritis through T Cell Suppression.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Berberine in rheumatoid arthritis: a comprehensive review and meta-analysis of its anti-inflammatory and immunomodulatory mechanisms in animal models.Inflammopharmacology · 2025Pooled it
- Unlocking the healing power of Berberine: A promising aid for multiple sclerosis.IBRO neuroscience reports · 2026Review
- A Comprehensive Review on Plant Bioactive Compounds-based Novel Drug Delivery System for the Treatment of Rheumatoid Arthritis.Pharmaceutical nanotechnology · 2026Review
- Targeting the osteoimmune microenvironment to prevent regulated chondrocyte death in osteoarthritis: therapeutic potential of natural products.Frontiers in cell and developmental biology · 2026Review
- Berberine as a natural immunomodulator of B lymphocytes.Inflammopharmacology · 2025Review
- Emerging Phytochemical Formulations for Management of Rheumatoid Arthritis: A Review.Current drug delivery · 2025Review
- When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms.Frontiers in immunology · 2024Review
- Research of Pathogenesis and Novel Therapeutics in Arthritis 3.0.International journal of molecular sciences · 2023Article
- Recent studies on berberine and its biological and pharmacological activities.EXCLI journal · 2023Article
- Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms.Frontiers in pharmacology · 2023Review
- The Flavonoid Naringenin Alleviates Collagen-Induced Arthritis through Curbing the Migration and Polarization of CD4International journal of molecular sciences · 2022Article
- Exploring the mechanism of berberine-mediated TPhytomedicine : international journal of phytotherapy and phytopharmacology · 2022Article
- Toxicity and toxicokinetics of the ethanol extract of Zuojin formula.BMC complementary medicine and therapies · 2022Article
- The bone-protective mechanisms of active components from TCM drugs in rheumatoid arthritis treatment.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is evidence that berberine (BBR), a clinically relevant plant compound, ameliorates clinically apparent collagen-induced arthritis (CIA) in vivo. However, to date, there are no studies involving the use of BBR which explore its prophylactic potential in this model of rheumatoid arthritis (RA). The aim of this study was to determine if prophylactic BBR use during the preclinical phase of collagen-induced arthritis would delay arthritic symptom onset, and to characterize the cellular mechanism underlying such an effect. DBA/1J mice were injected with an emulsion of bovine type II collagen (CII) and complete Freund's adjuvant (day 0) and a booster injection of CII in incomplete Freund's adjuvant (day 18) to induce arthritis. Mice were then given i.p. injections of 1 mg/kg/day of BBR or PBS (vehicle with 0.01% DMSO) from days 0 to 28, were left untreated (CIA control), or were in a non-arthritic control group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.